Davis Polk advised Xponential Fitness, while Latham & Watkins represented the underwriters in the offering. Xponential Fitness, Inc., the largest global franchisor of boutique fitness brands,...
Xponential Fitness’ Common Stock Offering
Shift4’s $575 Million Acquisition of Finaro
Latham & Watkins has advised Shift4 on the acquisition of Finaro, assisted by Conyers and Herzog, Fog & Neeman. Finaro (formerly Credorax), global cross-border payment provider...
LiveWire’s $1.77 Billion Merger with AEA-Bridges Impact Corp
Latham & Watkins represented Harley-Davidson, Inc. in the transaction, while Kirkland & Ellis counseled AEA-Bridges Impact Corp. Harley-Davidson, Inc. (NYSE: HOG), the world’s most desirable motorcycle...
nThrive’s $1.7 Billion Acquisition of TransUnion Healthcare
Latham & Watkins represented TransUnion in the transaction while Sidley advised nThrive. TransUnion (NYSE: TRU) has signed a definitive agreement to sell TransUnion Healthcare, Inc. to...
GlobalFoundries’ Initial Public Offering
Cleary Gottlieb Steen & Hamilton represented GlobalFoundries in the offering, while Latham & Watkins represented the underwriters. GlobalFoundries® (GF®), a global leader in feature-rich semiconductor manufacturing, announced...
Minerva Surgical’s $75 Million Initial Public Offering
Latham & Watkins represented the underwriters in the transaction. Minerva Surgical, Inc. (Minerva Surgical), a women’s health company focused on the treatment of Abnormal Uterine Bleeding (AUB),...
Xponential Fitness’ $120 Million Initial Public Offering
Davis Polk advised Xponential Fitness in its IPO, while Latham & Watkins represented the underwriters. Xponential Fitness, Inc. executed its $120 million initial public offering of 10,000,000...
Five Star Bancorp’s $94.8 Million Initial Public Offering
Latham & Watkins LLP represented the underwriters in the offering while Covington & Burling LLP advised Five Star Bancorp. Five Star Bancorp, a bank holding company...
Chardan Healthcare Acquisition 2 Corp.’s Merger with Renovacor
Latham & Watkins represented Chardan Healthcare Acquisition 2 Corp. in the transaction. Renovacor, Inc. (Renovacor), an early-stage biotechnology company developing AAV-based gene therapies for devastating cardiovascular...